pharmaphorum

JUNE 16, 2022

The litany of failed trials of amyloid-targeting drugs for Alzheimer’s disease has added another verse, as Roche concedes that its crenezumab candidate was unable to slow cognitive decline in patients with an inherited form of the disease. The result isn’t a big surprise – Roche terminated two phase 3 trials of crenezumab in people with prodromal to mild sporadic Alzheimer’s in early 2019 after interim analyses found it would be futile to continue – but is another blow to the

Immunization 109

Immunization 109

PharmaVoice

JUNE 16, 2022

An effective treatment for psychiatric disorders such as schizophrenia might require a holistic approach to avoid serious side effects, says CEO Steve Paul.

98

98

pharmaphorum

JUNE 16, 2022

When creating engagement plans for individual Digital Key Opinion Leaders (DOLs), it’s best to look at a range of data-led metrics about each DOL to fine tune the engagement and maximise benefit for all parties. The simplest, and often easiest metrics to obtain, relate to the activity characteristics of the Digital KOL. In Twitter for example, this may equate to the DOL’s activity levels, follower numbers, and so on.

101

101

PharmExec

JUNE 16, 2022

Recent increases in employee burnout and turnover must be addressed.

122

122

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

pharmaphorum

JUNE 16, 2022

In this episode of the pharmaphorum podcast, editor in chief Jonah Comstock welcomes Dr. Jennifer Jones-McMeans, divisional vice president for global affairs for Abbott’s vascular business to discuss diversity and equity in clinical trials. They discuss the nitty-gritty of clinical trial diversity – why it’s been so hard to achieve, why it’s important, and how to overcome the specific barriers to inclusion for different underrepresented communities.

99

99

Outsourcing Pharma

JUNE 16, 2022

This monthâs announcements on new products, enhanced technology, partnerships, and more includes Eversana, Thermo Fisher Scientific, and other notable companies.

52

52

Outsourcing Pharma

JUNE 16, 2022

The Biotechnology Innovation Organization elected the fresh slate of leaders during the BIO International Convention, taking place in San Diego this week.

52

52

pharmaphorum

JUNE 16, 2022

A personalised, treatment plan for patients with breast cancer is the first digital health product to emerge from a newly-announced partnership between digital health specialist Sidekick and pharma group Eli Lilly. The two companies say the integrated digital therapeutic (DTx) for breast cancer will aim to promote behaviour modifications to improve the wellbeing of breast cancer patients as well as adherence to drug treatment, foe example by managing side effects.

Health Insurance Companies 89

Health Insurance Companies Insurance 89

PharmExec

JUNE 16, 2022

Addressing sources of tension on differentiating types of data.

52

52

pharmaphorum

JUNE 16, 2022

In part one of this two-article series on the latest on England’s Innovative Medicines Fund (IMF), Leela Barham examined what the IMF is and what is known about how it will work. In part two, Leela explores some of the questions that remain about whether the IMF will add value and serve its purpose. Political capital. When it comes to politics there can be a lot of value added from approaches like the IMF and the CDF.

52

52

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Pharmaceutical Commerce

JUNE 16, 2022

Endeavor aims to tackle diversity obstacles surrounding this segment, while improving the patient experience.

52

52

pharmaphorum

JUNE 16, 2022

HiDoc Technologies has secured a cash injection of $7 million to help with the launch of its Cara Care digital therapeutic for people with irritable bowel syndrome (IBS), and fund a move into additional therapeutic categories. Use of the funding – which takes the total raised by the German digital health company to $16 million – will be overseen by a new chief executive, Jim Mapes, who joins from Optum, a division of US insurer UnitedHealth Group.

Insurance 52

Insurance FDA 52

Pharma Times

JUNE 16, 2022

The companies will focus on the development of biomarkers for chronic diseases

40

40

pharmaphorum

JUNE 16, 2022

Sweden’s Hansa Biopharma has claimed a positive opinion from NICE for Idefirix, which becomes the first drug cleared for NHS use in a group of kidney transplant patients for whom finding a donor is particularly challenging. Around a third of patients waiting for a kidney transplant are cases as “sensitised” – meaning they have very high antibody levels to human leukocyte antigens (HLAs), which makes it more likely they will reject a donated organ.

52

52

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

Pharma Times

JUNE 16, 2022

The MT-RNR1 test was assessed under NICE’s diagnostics assessment programme

36

36

pharmaphorum

JUNE 16, 2022

The FDA’s vaccines advisors have voted in favour of extending the use of mRNA-based COVID-19 vaccine from Moderna and Pfizer/BioNTech to include children from the ages of six months. The Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted 21 to zero in favour of both vaccines in this age group, in light of rising rates of hospitalisations and deaths that have been seen in the very young during the Omicron wave of infections.

FDA 52

FDA Vaccines 52

The Luxe Pharmacist

JUNE 16, 2022

Hi pharmily! Cheers to the beginning of summer and the start of APPE rotations for so many rising P4 pharmacy students! APPEs are such an incredible experience but I know the idea of going on rotations after classroom learning, mixed in with post graduation soul searching and preparation can be a bit daunting. I did a pharmacy school panel the other week actually and these topics came up a ton so I figured I’d round up my biggest tips for a successful APPE year into one convenient post.

Compounding 52

Compounding Patient Care 52

pharmaphorum

JUNE 16, 2022

Spinal muscular atrophy (SMA) is a devastating, genetic neuromuscular disease caused by a lack of a functional SMN1 gene that results in the progressive and irreversible loss of motor neurons. SMA affects approximately one in 10,000 live births worldwide. The loss of motor neurons affects muscle functions, like breathing, swallowing, and walking. SMA, though a rare disease, is the leading genetic cause of infant death.

45

45